Changing coronary event rates had a greater contribution than changing survival to the observed decline in CHD mortality
Data support longer recurrence‐free survival with nivolumab than with ipilimumab for stage III or IV melanoma
Improved survival, disparate outcomes contemporaneously define the modern worldwide burden of childhood cancers
